In order to assess the impact that DCLK1 has on HNSCC tumorigenesis, seven head and neck cell lines including, JHU-029, JHU-022, SCC25, JHU011, FaDu, Cal27 and SCC22b, were treated with a small molecule kinase inhibitor LRRK2-IN-1, which was reported to potently inhibit DCLK1 kinase activity (31, 32). Here, DCLK1 is linked to head and neck squamous cell carcinoma.